Saridegib free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201572

CAS#: 1037210-93-7 (free base)

Description: Saridegib, also known as Patidegip and IPI-926, is an orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Saridegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival.


Chemical Structure

img
Saridegib free base
CAS# 1037210-93-7 (free base)

Theoretical Analysis

MedKoo Cat#: 201572
Name: Saridegib free base
CAS#: 1037210-93-7 (free base)
Chemical Formula: C29H48N2O3S
Exact Mass: 504.34
Molecular Weight: 504.770
Elemental Analysis: C, 69.00; H, 9.58; N, 5.55; O, 9.51; S, 6.35

Price and Availability

Size Price Availability Quantity
5mg USD 1650 2 Weeks
10mg USD 2950 2 Weeks
Bulk inquiry

Related CAS #: 1037210-93-7 (free base)   1169829-40-6 (HCl)    

Synonym: IPI 926; IPI-926; IPI926; Saridegib; Patidegip; Patidegib Free Base; WHO9619; WHO-9619; WHO 9619

IUPAC/Chemical Name: N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulen]-3'-yl)methanesulfonamide

InChi Key: HZLFFNCLTRVYJG-WWGOJCOQSA-N

InChi Code: InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1

SMILES Code: CS(=O)(N[C@H](CC[C@@]12C)C[C@@]1([H])CC[C@]3([H])[C@]2([H])CC4=C(C)C[C@@](O5)(CC[C@@]34[H])[C@H](C)[C@@]6([H])[C@@]5([H])C[C@H](C)CN6)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:    Fig 1. Chemical structure comparison between IPI-926 and cyclopamine   IPI-926 is currently developed by Infinity Pharmaceuticals, Inc. Malignant activation of the Hedgehog pathway is implicated in multiple cancer settings and Infinity's development strategy is designed to enable IPI-926 to target a broad range of critical oncology targets - from the tumor cell to the cancer microenvironment. This broadly applicable, targeted approach represents an innovative method for fighting cancer and has potential in treating a range of cancers, including pancreatic cancer, small cell lung cancer, ovarian cancer, bladder cancer, medulloblastoma, basal cell carcinoma, and certain hematological malignancies.       

Product Data:
Safety Data Sheet (SDS):
Biological target: Saridegib is a potent and specific Smo inhibitor.
In vitro activity: Saridegib potential therapeutic agent for human B-cell acute lymphocytic leukemia (B-ALL). The expression of Hh pathway components was common in B-ALL cell lines and clinical samples. Saridegib modulated Hh pathway activity in B-ALL cells. The primary impact of inhibiting this pathway activity was on highly clonogenic B-ALL cells that expressed aldehyde dehydrogenase (ALDH), limiting their self-renewal potential. Reference: PLoS One. 2010 Dec 28;5(12):e15262. https://pubmed.ncbi.nlm.nih.gov/21203400/
In vivo activity: This study evaluated saridegib in combination with FOLFIRINOX in patients with advanced pancreatic cancer. The objective response rate was high (67%), and patients receiving saridegib maintenance showed further declines in CA19-9 levels even after FOLFIRINOX discontinuation. Treatment did not result in consistent increases in tumor perfusion. This study closed early when a separate phase II trial of saridegib plus gemcitabine indicated detrimental effects of this combination. Reference: Pancreas. 2016 Mar;45(3):370-5. https://pubmed.ncbi.nlm.nih.gov/26390428/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 10.0 19.81

Preparing Stock Solutions

The following data is based on the product molecular weight 504.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Ma H, Tian Y, Yu X. Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. Med Sci Monit. 2017 Mar 28;23:1493-1500. doi: 10.12659/msm.903012. PMID: 28350784; PMCID: PMC5381338. 2. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010 Dec 28;5(12):e15262. doi: 10.1371/journal.pone.0015262. PMID: 21203400; PMCID: PMC3011010. 3. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458. PMID: 26390428; PMCID: PMC5908466. 4. Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:74-9. doi: 10.1016/j.oraloncology.2015.11.014. Epub 2015 Dec 15. PMID: 26705064; PMCID: PMC5676309.
In vitro protocol: 1. Ma H, Tian Y, Yu X. Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. Med Sci Monit. 2017 Mar 28;23:1493-1500. doi: 10.12659/msm.903012. PMID: 28350784; PMCID: PMC5381338. 2. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010 Dec 28;5(12):e15262. doi: 10.1371/journal.pone.0015262. PMID: 21203400; PMCID: PMC3011010.
In vivo protocol: 1. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458. PMID: 26390428; PMCID: PMC5908466. 2. Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:74-9. doi: 10.1016/j.oraloncology.2015.11.014. Epub 2015 Dec 15. PMID: 26705064; PMCID: PMC5676309.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1. Austad, B.; Bahadoor, A.; Belani, J. D.; Janardanannair, S.; Johannes, C. W.; Keaney, G. F.; Lo, C. K.; Wallerstein, S. L. Enzymatic transamination of cyclopamine analogs. WO2011017551A1.